Literature DB >> 10403922

Comparison of enterovirus-specific cellular immunity in two populations of young children vaccinated with inactivated or live poliovirus vaccines.

S Juhela1, H Hyöty, R Uibo, S H Meriste, O Uibo, M Lönnrot, M Halminen, O Simell, J Ilonen.   

Abstract

Enterovirus-specific cellular immunity was studied in Estonian and in Finnish children at the age of 9 months. The aim was to evaluate the level of responsiveness in two neighbouring countries with different poliovirus immunization practices and striking differences in the incidence of insulin-dependent diabetes mellitus (IDDM), a disease in which early enterovirus infections are an aetiological risk factor. The Estonian children immunized with live attenuated polio vaccine had stronger T cell responses to coxsackievirus B4 and poliovirus type 1 when compared with Finnish children immunized with inactivated polio vaccine (median stimulation indices 10.4 and 6.3 in Estonian children and 1.9 and 2.9 in Finnish children, respectively; P < 0.05). Lymphocytes stimulated by poliovirus type 1 antigen expressed interferon-gamma (IFN-gamma) mRNAs, which strongly correlated with the level of proliferation responses. Lymphocytes of Estonian children had a tendency towards stronger expression of IFN-gamma upon poliovirus challenge when compared with Finnish children. The number of children who had experienced coxsackievirus B infections, as determined by the presence of neutralizing antibodies, did not differ between Estonian and Finnish children. The results show that Finnish children have weaker cellular immunity against enteroviruses at the age of 9 months compared with Estonian children at the same age. This is most probably due to the difference in polio vaccination schedules; in Estonia live poliovirus vaccine is used and given at earlier ages than the inactivated vaccines in Finland. This leads to stronger T cell immunity which cross-reacts with other enterovirus serotypes. This may explain the lower incidence of IDDM in Estonia by providing effective protection against diabetogenic enterovirus strains in Estonian children.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10403922      PMCID: PMC1905481          DOI: 10.1046/j.1365-2249.1999.00954.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

Review 1.  Immunisation and type 1 diabetes mellitus: is there a link?

Authors:  M Hiltunen; M Lönnrot; H Hyöty
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

Review 2.  Enteroviruses in human disease.

Authors:  N R Grist; E J Bell; F Assaad
Journal:  Prog Med Virol       Date:  1978

3.  Chronic neonatal coxsackie myocarditis.

Authors:  A Goren; M Kaplan; J Glaser; M Isacsohn
Journal:  Arch Dis Child       Date:  1989-03       Impact factor: 3.791

4.  Secondary enterovirus infection in the murine model of myocarditis. Pathologic and immunologic aspects.

Authors:  M A Beck; N M Chapman; B M McManus; J C Mullican; S Tracy
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

5.  Purification of adenovirus hexon protein by high-performance liquid chromatography.

Authors:  M Waris; P Halonen
Journal:  J Chromatogr       Date:  1987-06-26

6.  T lymphocyte responses to Coxsackie B4 and mumps virus. II. Immunoregulation by HLA-DR3 and -DR4 associated restriction elements.

Authors:  O Bruserud; M Stenersen; E Thorsby
Journal:  Tissue Antigens       Date:  1985-09

7.  Comoviruses and enteroviruses share a T cell epitope.

Authors:  M A Beck; S Tracy; B A Coller; N M Chapman; G Hufnagel; J E Johnson; G Lomonossoff
Journal:  Virology       Date:  1992-01       Impact factor: 3.616

8.  The relationship between immune interferon production and proliferation in antigen-specific, MHC-restricted T cell lines and clones.

Authors:  T T Hecht; D L Longo; L A Matis
Journal:  J Immunol       Date:  1983-09       Impact factor: 5.422

9.  HLA-DR3 and -DR4 control T-lymphocyte responses to mumps and Coxsackie B4 virus: studies on patients with type 1 (insulin-dependent) diabetes and healthy subjects.

Authors:  O Bruserud; J Jervell; E Thorsby
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

10.  Evidence for a group-specific enteroviral antigen(s) recognized by human T cells.

Authors:  M A Beck; S M Tracy
Journal:  J Clin Microbiol       Date:  1990-08       Impact factor: 5.948

View more
  5 in total

Review 1.  Enterovirus and type 1 diabetes: What is the matter?

Authors:  Carla Sanchez Bergamin; Sergio Atala Dib
Journal:  World J Diabetes       Date:  2015-06-25

2.  Diagnostic potential of parechovirus capsid proteins.

Authors:  Annu Alho; Jane Marttila; Jorma Ilonen; Timo Hyypiä
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

3.  Viral interference induced by live attenuated virus vaccine (OPV) can prevent otitis media.

Authors:  Elina Seppälä; Hanna Viskari; Sanna Hoppu; Hanna Honkanen; Heini Huhtala; Olli Simell; Jorma Ilonen; Mikael Knip; Heikki Hyöty
Journal:  Vaccine       Date:  2011-09-20       Impact factor: 3.641

Review 4.  A systematic approach to virus-virus interactions.

Authors:  T DaPalma; B P Doonan; N M Trager; L M Kasman
Journal:  Virus Res       Date:  2010-01-20       Impact factor: 3.303

Review 5.  Enteroviruses, type 1 diabetes and hygiene: a complex relationship.

Authors:  S Tracy; K M Drescher; J D Jackson; K Kim; K Kono
Journal:  Rev Med Virol       Date:  2010-03       Impact factor: 6.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.